Peptide Receptor Radionuclide Therapy (PRRT)

Рет қаралды 8,446

Күн бұрын

One of the most significant treatment options for neuroendocrine cancer patients became available with the 2018 FDA approval of Lutathera®, the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT).
NET experts Dr. Emily Bergsland, Dr. Pamela Kunz, Dr. Erik Mittra and Dr.
Jonathan Strosberg describe the treatment, how it works, and the benefits for patients.
What do physicians look forward to in the future for PRRT?

Пікірлер: 12

@latasha3472 3 жыл бұрын

I completed this treatment last year and it definitely work my tumor definitely shrunk a lot and I have less symptoms now.

@CarcinoidNETs 3 жыл бұрын

Thanks so much for sharing the positive effects of your treatment, Latasha.

@pdrey100 2 жыл бұрын

What was your original tumor size and what was your SUVmax value from a dotatate scan pre treatment? Thank you.

@kenburk4245 Жыл бұрын

I'm down to my last infusion in Jan 2023. Really looking forward to my first scan after treatment.

@loveleighmurf 3 жыл бұрын

It does seem to be the first line of treatment for pheochromocytoma/parangaliomas if inoperable (and if they are a candidate for it)

@vamsinadh3159 3 жыл бұрын

When alpha emitter is suggested. Is ac-225 is safer than lu-177

@CarcinoidNETs 3 жыл бұрын

Hi Vamsi, here's an article that may answer your questions regarding the difference between using alpha emitters versus beta emitters in PRRT, www.sciencedirect.com/science/article/pii/S000129981930100X. This is definitely a question to raise with your own physician/team of physicians.

@umarsalafi8306 3 жыл бұрын

how many doses of prrt therapy can you have maximum

@latasha3472 3 жыл бұрын

I read 10

@johnrivas2710 3 жыл бұрын

Has this treatment been tested on patients with poorly differentiated or high grade neuroendocrine carcinoma? If so what was the result?

@CarcinoidNETs 3 жыл бұрын

Hi John, here are some articles that might be of interest regarding PRRT and poorly differentiated neuroendocrine tumors, PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3), erc.bioscientifica.com/view/journals/erc/27/3/ERC-19-0400.xml, and an abstract from a study, Treatment of High Grade Metastatic Neuroendocrine Tumor (mNET) with Peptide Receptor Radionuclide Therapy (PRRT) Retrospective Analysis in a Single Referral Center, nanets.net/abstracts-archive/2015/363-c05-treatment-of-high-grade-metastatic-neuroendocrine-tumor-mnet-with-peptide-receptor-radionuclide-therapy-prrt-retrospective-analysis-in-a-single-referral-center/file. We hope these provide helpful information.

@latasha3472 2 жыл бұрын

I have high grade neuroendocrine pancreatic and it worked beautifully my tumor shrunk a lot